XXXX : incidence according to ductal or lobular phenotype of the primary.

@entity1 @entity1137 @entity0 @entity5 @entity513
AIM: To identify differences in the incidence of @entity0 between @entity1 with a primary @entity5 diagnosis of @entity513 ( @entity513 ) and those with a diagnosis of @entity1137 ( @entity1137 ). MATERIALS AND METHODS: Data from two large @entity5 registries (registry A _ B) the Northern and Yorkshire Cancer Registry Information Service (NYCRIS) and the West Midlands Cancer Intelligence Unit (WMCIU) from 1998-2003 for all cases of @entity0 of either pure ductal or pure lobular reported histology were obtained. The invasive status of the @entity5 diagnosis and @entity5 morphology was collected. Chi-square tests were undertaken to examine the differences in contralateral rates for both registries and univariate analysis to ascertain which predictors affected @entity0 risk for registry A the WMCIU cases. RESULTS: A total of 38,132 @entity1 were studied, 32,735 @entity1 with @entity513 and 5397 (14.2%) @entity1 with @entity1137 over the 6-year period. There was no significant difference between the occurrence and time to occurrence of @entity0 according to original @entity5 histology, 901 (2.8%) @entity1 with @entity513 versus 166 (3.1%) @entity1 with @entity1137 (p=0.169). The analysis of registry A cases showed no association between original histology (ductal versus lobular), age at diagnosis, @entity5 grade, use of radiotherapy for the primary @entity5 or use of systemic therapy (chemotherapy and/or endocrine therapy), and development of a @entity0 . CONCLUSION: There is no apparent increase in risk of developing a @entity0 according to the primary @entity5 histology either @entity513 or @entity1137 . Standard mammographic follow-up does not need to take account of original @entity5 pathology. Increased intervention or post-treatment surveillance for the contralateral breast is not indicated in the context of @entity1137 . The role of MRI should be restricted to those @entity1 with @entity1137 who are planning breast-conservation surgery, but not for assessing the contralateral breast.
